Summary: In healthy adult volunteers (Japanese n=20-21, non-Japanese n=20-21), single-dose cilofexor 100 mg or firsocostat 20 mg showed higher plasma…
Browsing: MASLD / Fatty Liver
Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH), MASH, and liver-directed metabolic therapy.
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
A published study protocol for a 52-week double-blind randomised trial of semaglutide plus empagliflozin versus each drug alone for NAFLD in type 2 diabetes. No efficacy results are reported yet. PICO summary and expert commentary.
Design and baseline characteristics of the phase 3 ESSENCE trial of weekly semaglutide 2.4 mg in 800 participants with biopsy-proven MASH and fibrosis stage 2 or 3, with no efficacy results reported yet. PICO summary and expert commentary.
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater…